Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07693153 · ClinicalTrials.gov registry record · Phase 1
The Effects of Psilocybin on Social Connectedness
A Phase 1 study, sponsored by Yale University.
- Not yet
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT07693153 is a Phase 1 study that has not yet begun recruiting, run by Yale University. The registered enrollment target is 51 participants.
The verdict
NCT07693153, a Phase 1 study, has not yet begun recruiting, sponsored by Yale University.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
The study is a randomized, double-blind, placebo-controlled, expectancy-controlled, mechanistic trial. This study looks to explore whether a single dose of psilocybin (25mg) reduces amygdala reactivity to negative socioemotional stimuli during the Facial Emotion Recognition Task (FERT) compared to a placebo in adults who feel lonely or those with unresolved grief symptoms.
Interventions
- DRUG Placebo
- DRUG Psilocybin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2026-08-31 |
| Est. Completion | 2031-12-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07693153
The ClinicalTrials.gov registry entry for NCT07693153 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07693153 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07693153 about?
NCT07693153 is a clinical study titled "The Effects of Psilocybin on Social Connectedness". The study is a randomized, double-blind, placebo-controlled, expectancy-controlled, mechanistic trial. This study looks to explore whether a single dose of psilocybin (25mg) reduces amygdala reactivity to negative socioemotional stimuli during the Facial Emotion Recognition Task (FERT) compared to a...
What is the current status of trial NCT07693153?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2026-08-31. Estimated completion is 2031-12-15.
What interventions are being tested in trial NCT07693153?
The interventions under investigation include: Placebo (DRUG), Psilocybin (DRUG).
Who is sponsoring clinical trial NCT07693153?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.